SUT BEZI SARATONIDA ONKOMARKERLAR VA IMMUNOGISTOKIMYOVIY TEKSHIRUVLARNING DIAGNOSTIK AHAMIYATI
Article Sidebar
Main Article Content
Аннотация:
Sut bezi saratonini aniqlash va monitoring qilishda biokimyoviy markerlarning diagnostik va prognostik ahamiyati baholandi. Tadqiqot jarayonida CA 15-3, karsinoembrional antigen (CEA), HER2/neu va estrogen retseptorlari kabi o‘sma markerlarining klinik qo‘llanilishi tahlil qilindi[2,3,4]. Natijalar ushbu markerlarning kasallikni erta aniqlash, davolash samaradorligini baholash hamda residiv va metastazlar xavfini prognoz qilishda muhim ahamiyatga ega ekanini ko‘rsatdi[2,3]. Luminal A — sut bezi saratonining eng ko‘p uchraydigan va eng qulay prognozga ega bo‘lgan immunogistokimyoviy turi hisoblanadi[7,9]. Bu tur o‘sma hujayralarida estrogen (ER) va progesteron (PR) retseptorlarining yuqori darajada ifodalanishi, HER2 onkoproteinining manfiy bo‘lishi hamda Ki-67 proliferativ indeksining pastligi bilan xarakterlanadi[5,7].Mazkur turdagi o‘smalar odatda sekin o‘sadi, kam invaziv bo‘ladi va uzoq muddatli yashovchanlik ko‘rsatkichlari yuqori hisoblanadi[9]. Luminal A turida gormonal regulyatsiya asosiy rol o‘ynaganligi sababli, o‘sma hujayralari gormonal terapiyaga yaxshi javob beradi[3].Luminal A turidagi bemorlarda gormonal davolash (tamoksifen, aromataza ingibitorlari) asosiy tanlov bo‘lib, ko‘pincha kimyoterapiyasiz ham samarali natijalarga erishiladi[3].
Article Details
Как цитировать:
Библиографические ссылки:
Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA: A Cancer Journal for Clinicians, 2021, 71(3): 209–249.
Duffy M. J.
Serum tumor markers in breast cancer: Are they of clinical value?
Clinical Chemistry, 2006, 52(3): 345–351.
Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S.
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Journal of Clinical Oncology, 2007, 25(33): 5287–5312.
Hayes D. F.
Tumor markers for breast cancer.
Annals of Oncology, 1993, 4(10): 807–819.
Perou C. M., Sørlie T., Eisen M. B., van de Rijn M., Jeffrey S. S., Rees C. A.
Molecular portraits of human breast tumours.
Nature, 2000, 406(6797): 747–752.
Ross J. S., Fletcher J. A.
The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy.
The Oncologist, 1998, 3(4): 237–252.
Sørlie T., Perou C. M., Tibshirani R., Aas T., Geisler S., Johnsen H.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
Proceedings of the National Academy of Sciences of the USA, 2001, 98(19): 10869–10874.
World Health Organization.
Breast cancer: prevention and control.
Geneva, 2023.
Yersal O., Barutca S.
Biological subtypes of breast cancer: Prognostic and therapeutic implications.
World Journal of Clinical Oncology, 2014, 5(3): 412–424.